Unlocking Autophagy: How a Key Protein Target Could Revolutionize Cancer Treatment
"Scientists identify USP1 as a critical regulator of autophagy, opening new avenues for targeted cancer therapies."
In the relentless battle against cancer, scientists are constantly seeking new vulnerabilities within cancer cells to exploit. One promising area of research is autophagy, a cellular "self-eating" process that, paradoxically, can help cancer cells survive under stress. New research has identified a key protein, USP1, as a critical regulator of this process, offering a potential new target for cancer therapies.
Autophagy, or macroautophagy, is a fundamental process where cells degrade and recycle their own components. It acts like a cellular cleaning service, removing damaged proteins and organelles. While it can be a protective mechanism, cancer cells often hijack autophagy to survive harsh conditions, such as nutrient deprivation or chemotherapy. By understanding how autophagy is regulated, researchers hope to develop strategies to disrupt this survival mechanism and make cancer cells more vulnerable.
The new study, led by researchers at L.N.C.I.B. Laboratorio Nazionale Consorzio Interuniversitario Biotecnologie and the University of Udine, Italy, sheds light on the role of USP1 (ubiquitin-specific peptidase 1) in regulating autophagy. Their findings reveal that USP1 targets ULK1, a key protein involved in initiating autophagy, and regulates its activity and location within the cell. This discovery opens up exciting possibilities for developing targeted therapies that disrupt autophagy and enhance the effectiveness of existing cancer treatments.
Promise and Limits of Autophagy Targeting
Reviews describe targeting autophagy as a potential cancer strategy, particularly when integrated with existing treatments, but emphasize that its regulation is complex and that side effects remain a concern. One 2024 review says many approaches can make cancer cells more receptive to standard chemotherapy, while also noting that studies differ on whether autophagy promotes or suppresses cancer. ATTEC is described as offering potential advantages, including targeting multiple oncogenic targets and use across a wide range of cancer types, but precise, context-specific approaches require further research.
A Timeline of Autophagy and Cancer Research
A 2020 review frames the past 20 years of autophagy-and-cancer research around identification of the molecular machinery involved in autophagy. It summarizes the pathway’s mechanism and its involvement in cancer, and discusses its potential as a therapeutic target. A 2018 historical perspective likewise recounts the history of autophagy while identifying unanswered cell-biological questions.
What is USP1 and How Does It Control Autophagy?
USP1 is an enzyme known as a deubiquitinase (DUB). DUBs are responsible for removing ubiquitin tags from proteins. Ubiquitination is a process that modifies proteins, affecting their function, location, or stability. By removing ubiquitin tags, USP1 can reverse these modifications and alter the behavior of its target proteins. Previous research has linked USP1 to DNA repair processes, making it an attractive target for cancer therapy.
- USP1 Depletion: When USP1 is depleted, ULK1 becomes less soluble in cells and accumulates in specific compartments.
- Pimozide Inhibition: Pimozide, an USP1 inhibitor, leads to similar effects, suggesting that USP1 activity is crucial for maintaining ULK1 function and location.
- SQSTM1 Interaction: ULK1 interacts with SQSTM1, a protein involved in selective autophagy, indicating a connection between USP1, ULK1, and the targeted degradation of specific cellular components.
ULK1 as a Potential Autophagy Target
A study titled “A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress” reports that loss of ULK1 alone is sufficient to abrogate autophagy in many cell types, despite ULK2 also promoting autophagy. A 2026 review describes autophagy as a tumor-suppressive gatekeeper during cancer initiation, partly through preserving genomic stability, but says established tumors frequently co-opt it to support metabolic fitness and therapeutic resistance. The review also characterizes early clinical efforts using broad, non-selective lysosomal inhibition as a relevant part of the field’s history.
Why Autophagy Inhibition Can Fall Short
A preclinical lung-cancer study suggests that limited results with hydroxychloroquine (HCQ) could reflect its relatively low potency as an autophagy inhibitor, the lower mutational burden of tumors in genetically engineered mouse (GEM) models compared with human cancers, or use of nonspecific inhibitors. Reviews also stress that autophagy can inhibit tumor initiation in some contexts while supporting established cancers through treatment resistance, metabolic changes, and immunosuppression. A pancreatic-cancer study reports that ULK1 helps maintain an immunosuppressive tumor microenvironment, but says the immune-cell mechanisms need further investigation under physiological conditions.
Autophagy’s Opposing Roles in Cancer
A 2023 Nature review describes seemingly opposing roles for autophagy: preventing early tumor development while supporting the maintenance and metabolic adaptation of established tumors. A separate review likewise characterizes autophagy as having dual functions that can either promote or suppress tumor growth. It also reviews recent cancer-therapy research and novel anti-cancer agents developed in the preceding five years that target autophagy.
The Future of Cancer Therapy: Targeting USP1
These findings suggest that USP1 could be a valuable target for cancer therapy, particularly in tumors that rely heavily on autophagy for survival. By inhibiting USP1, researchers aim to disrupt autophagy, making cancer cells more vulnerable to traditional treatments. The study provides evidence that the USP1 inhibitor pimozide can affect breast cancer cell growth, suggesting a potential therapeutic strategy.
Emerging Targets and Contexts
A 2023 review identifies newly discovered regulatory mechanisms of mammalian autophagy as potential future targets for drug discovery. It proposes examining cancer contexts in which autophagy modulation may be safe and effective. The review also points to therapeutics emerging in preclinical studies and clinical trials to modulate autophagy in cancer.